AI
Monday, June 19, 2006 3:09:06 PM
Re: VX-950 survey
<< In any case, the survey is already written and some people have voted, so I’d better leave it alone. <<
No biggie. I already posted my guess anyway , so I can still claim bragging rights if I'm right about the final outcomes.
Boger has confidence in the high-sensitivity Taqman ( 10 IU/ml) to give an earlier indication of SVR , so he'll have the information he needs well before the 6-month SVR time point.
I'd imagine that the FDA will be pressured at some point , maybe based on the VRTX P2 data , to change the SVR criteria to allow earlier measures and thus speed up HCV trials.
There's also work being done on an HCV core Ag assay that has shown some predictive utility. Maybe a combination of HS Taqman and core Ag assays will someday accurately predict SVR while on-treatment.
<< In any case, the survey is already written and some people have voted, so I’d better leave it alone. <<
No biggie. I already posted my guess anyway , so I can still claim bragging rights if I'm right about the final outcomes.
Boger has confidence in the high-sensitivity Taqman ( 10 IU/ml) to give an earlier indication of SVR , so he'll have the information he needs well before the 6-month SVR time point.
I'd imagine that the FDA will be pressured at some point , maybe based on the VRTX P2 data , to change the SVR criteria to allow earlier measures and thus speed up HCV trials.
There's also work being done on an HCV core Ag assay that has shown some predictive utility. Maybe a combination of HS Taqman and core Ag assays will someday accurately predict SVR while on-treatment.
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
